Dihydrofolate Reductase anticorps (AA 1-187)

N° du produit ABIN5540915

Cet anticorps Souris Monoclonal détecte spécifiquement Dihydrofolate Reductase dans WB et EIA. Il présente une réactivité envers Humain.

Aperçu rapide pour Dihydrofolate Reductase anticorps (AA 1-187) (ABIN5540915)

Antigène: Dihydrofolate Reductase (DHFR)

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Dihydrofolate Reductase est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Clone: AT5B2

Détail du produit anti-Dihydrofolate Reductase anticorps

Épitope: AA 1-187

Purification: Protein-A affinity chromatography

Immunogène: Recombinant human DHFR (1-187aa) purified from E. coli.

Isotype: IgG1

Information d'application

Indications d'application: The antibody has been tested by ELISA, Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Liquid. In Phosphate-Buffered Saline ( pH 7.4) with 0.02 % Sodium Azide, 10 % Glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch.

Date de péremption: 12 months

Détails sur Dihydrofolate Reductase

Antigène: Dihydrofolate Reductase (DHFR)

Autre désignation: dhfr,dhfrp1

Sujet: Dihydrofolate reductase (DHFR) catalyzes the DPH-dependent reduction of dihydrofolate to tetrahydrofolate, and is a crucial enzyme for the synthesis of purines, pyrimidines and some amino acids. Inhibition of the activity of this enzyme leads to arrest of D synthesis and cell death. Gene expression of methotrexate (MTX)-resistant variants of DHFR in normal hematopoietic cells is a potential strategy to permit administration of larger doses of MTX by alleviating drug toxicity in normal cells and tissues that are drug sensitive.

UniProt: P00374

Pathways: Mitotic G1-G1/S Phases